Factors influencing response to blinatumomab in relapsed/refractory ALL
Factors influencing response to blinatumomab in relapsed/refractory ALL
Evidence for kinase inhibitor activity in acute myeloid leukaemia
Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia
DNMT3A R882 mutations promote chemoresistance and residual disease in AML
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression
Treatment and survival of patients with chronic myeloid leukaemia in Europe
Expert overview on the recent developments in mantle cell lymphoma
Round-up of the latest research on lung cancer
Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma
Medically under-represented populations: Refining the calculation of accrual targets
Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer
Screening to identify unsuitable candidates for ipilimumab in advanced melanoma